Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill. Graciously taking the time to engage in conversation, Allen extended his gratitude to Dr. Abdou for joining the discussion.
In their exchange, the focus shifted to the intricate realm of medical practice, specifically exploring the practice patterns associated with the sequential use of antibody drug conjugates after antibody drugs. Dr. Yara Abdou delved into the complexities of this topic, shedding light on the challenges faced by providers in sequencing these drugs due to the yet-to-be-fully-understood efficacy of using a second antibody drug conjugate.
The doctor revealed the results of a survey conducted across the United States, featuring responses from 70% academic providers and 30% community oncologists. Notably, 50% of the prescribing providers expressed a belief that the efficacy of the second antibody drug conjugate might be lower than that demonstrated in the registration trials. This lack of uniformity in sequencing practices underscored the existing gap in knowledge, emphasizing the pressing need for further research on the matter.
As Allen probed into the future of this data, Dr. Yara Abdou articulated the next steps, envisioning clinical trials and real-world evidence studies as avenues to deepen the understanding of antibody drug conjugates post-antibody drug conjugates.
With the insightful discussion coming to a close, Allen expressed his gratitude once more to Dr. Yara Abdou, acknowledging her valuable contribution to the exploration of this challenging and evolving field within oncology.